**Background**
Benign prostatic hyperplasia (BPH) is a common condition characterized by the nonmalignant growth of the prostate gland, which often leads to lower urinary tract symptoms and impaired bladder emptying. Similarly, hypertension remains a global health challenge, requiring effective pharmacological interventions to reduce blood pressure and prevent cardiovascular complications. The $\alpha_1$-adrenoceptor plays a critical role in regulating the smooth muscle tone of both blood vessels and the bladder neck. By antagonizing these receptors, it is possible to relax the vascular system and open the bladder, providing therapeutic relief for patients with these conditions. In this context, we will introduce an orally active $\alpha_1$-adrenoceptor antagonist – Terazosin.
**Definition**
Terazosin is a quinazoline derivative that acts as a competitive $\alpha_1$-adrenoceptor antagonist. According to the Terazosin technical information, this compound is utilized to treat high blood pressure and BPH by relaxing smooth muscles in the blood vessels and the bladder.
**In Vitro and In Vivo Studies**
The Terazosin description highlights its utility across various experimental models. In terms of Terazosin in vitro activity, studies using COS cells have demonstrated that Terazosin does not discriminate between cloned $\alpha_1$-adrenoceptor subtypes that are transiently expressed. This suggests a broad antagonistic effect across the $\alpha_1$ receptor family.
Regarding Terazosin In Vivo applications, the compound has been investigated for its ability to promote stone discharge in the treatment of ureteral stones. Specifically, research indicates that Terazosin is safe and effective for the treatment of distal ureteral stones, particularly those with a diameter greater than 5 mm. Furthermore, combination therapies involving Terazosin and nifedipine have been explored to enhance postoperative outcomes following transurethral ureteroscopic lithotripsy. In conclusion, Terazosin is a potent $\alpha_1$-adrenoceptor antagonist with significant potential for treating BPH, hypertension, and distal ureteral stones.
Keywords
Terazosin, 63074-08-8, Adrenergic Receptor, Beta Receptor, α1-adrenoceptor, benign, prostatic, hyperplasia, high, blood, pressure, bladder, quinazoline, Inhibitor, inhibitor, inhibit
References
[1] Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.
[2] Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8.
[3] Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851.